Your browser doesn't support javascript.
loading
Clinical application of a GPU-accelerated monte carlo dose verification for cyberknife M6 with Iris collimator.
Zhou, Peng; Chang, Yankui; Li, Shijun; Luo, Jia; Lei, Lin; Shang, Yufen; Pei, Xi; Ren, Qiang; Chen, Chuan.
Afiliação
  • Zhou P; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
  • Chang Y; School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China.
  • Li S; School of Nuclear Science and Technology, University of Science and Technology of China, Hefei, China.
  • Luo J; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
  • Lei L; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
  • Shang Y; Department of Radiation Oncology, Dezhou Second People's Hospital, Dezhou, China.
  • Pei X; Anhui Wisdom Technology Company Limited, Hefei, China.
  • Ren Q; Anhui Wisdom Technology Company Limited, Hefei, China. sr_qren@163.com.
  • Chen C; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China. sinkriver@126.com.
Radiat Oncol ; 19(1): 86, 2024 Jul 02.
Article em En | MEDLINE | ID: mdl-38956685
ABSTRACT

PURPOSE:

To apply an independent GPU-accelerated Monte Carlo (MC) dose verification for CyberKnife M6 with Iris collimator and evaluate the dose calculation accuracy of RayTracing (TPS-RT) algorithm and Monte Carlo (TPS-MC) algorithm in the Precision treatment planning system (TPS).

METHODS:

GPU-accelerated MC algorithm (ArcherQA-CK) was integrated into a commercial dose verification system, ArcherQA, to implement the patient-specific quality assurance in the CyberKnife M6 system. 30 clinical cases (10 cases in head, and 10 cases in chest, and 10 cases in abdomen) were collected in this study. For each case, three different dose calculation methods (TPS-MC, TPS-RT and ArcherQA-CK) were implemented based on the same treatment plan and compared with each other. For evaluation, the 3D global gamma analysis and dose parameters of the target volume and organs at risk (OARs) were analyzed comparatively.

RESULTS:

For gamma pass rates at the criterion of 2%/2 mm, the results were over 98.0% for TPS-MC vs.TPS-RT, TPS-MC vs. ArcherQA-CK and TPS-RT vs. ArcherQA-CK in head cases, 84.9% for TPS-MC vs.TPS-RT, 98.0% for TPS-MC vs. ArcherQA-CK and 83.3% for TPS-RT vs. ArcherQA-CK in chest cases, 98.2% for TPS-MC vs.TPS-RT, 99.4% for TPS-MC vs. ArcherQA-CK and 94.5% for TPS-RT vs. ArcherQA-CK in abdomen cases. For dose parameters of planning target volume (PTV) in chest cases, the deviations of TPS-RT vs. TPS-MC and ArcherQA-CK vs. TPS-MC had significant difference (P < 0.01), and the deviations of TPS-RT vs. TPS-MC and TPS-RT vs. ArcherQA-CK were similar (P > 0.05). ArcherQA-CK had less calculation time compared with TPS-MC (1.66 min vs. 65.11 min).

CONCLUSIONS:

Our proposed MC dose engine (ArcherQA-CK) has a high degree of consistency with the Precision TPS-MC algorithm, which can quickly identify the calculation errors of TPS-RT algorithm for some chest cases. ArcherQA-CK can provide accurate patient-specific quality assurance in clinical practice.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dosagem Radioterapêutica / Algoritmos / Planejamento da Radioterapia Assistida por Computador / Método de Monte Carlo / Radiocirurgia / Órgãos em Risco Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dosagem Radioterapêutica / Algoritmos / Planejamento da Radioterapia Assistida por Computador / Método de Monte Carlo / Radiocirurgia / Órgãos em Risco Idioma: En Ano de publicação: 2024 Tipo de documento: Article